GlassScriptPhysician profile
Pavan Pamadurthi
NPI 1982835112
$3,674.77
in general payments reported to CMS, 2019-2025
28 companies · $445 in 2025
The $445 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $412 · 2020: $296 · 2021: $517 · 2022: $687 · 2023: $754 · 2024: $565 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,709 · Education: $54.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,709.09 |
| Education | $54.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $654.71 | 2021-2025 | |
| Alkermes, INC. | $425.48 | 2022-2025 | Lybalvi, Aristada |
| Janssen Pharmaceuticals, INC | $365.49 | 2019-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Otsuka America Pharmaceutical, INC. | $354.20 | 2019-2025 | Rexulti, Abilify Maintena |
| Takeda Pharmaceuticals U.S.A., INC. | $327.80 | 2019-2022 | |
| Vanda Pharmaceuticals INC. | $224.48 | 2020-2025 | Fanapt |
| Supernus Pharmaceuticals, INC. | $168.53 | 2023-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $152.93 | 2023 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $123.73 | 2024-2025 | Cobenfy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $116.79 | 2021-2022 | |
| Lundbeck LLC | $108.38 | 2019-2024 | Rexulti |
| Sunovion Pharmaceuticals INC. | $94.71 | 2021-2022 | |
| Allergan, INC. | $88.63 | 2019-2020 | |
| Corium, LLC | $76.22 | 2022-2024 | Azstarys |
| Vertical Pharmaceuticals, LLC | $60.48 | 2025 | Relexxii |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $53.85 | 2020-2021 | |
| Brainsway USA INC | $48.77 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $46.80 | 2024 | Uzedy |
| Owp Pharmaceuticals, INC. | $24.30 | 2023 | Subvenite, Lamotrigine |
| Acadia Pharmaceuticals INC | $22.56 | 2019 | |
| Axsome Therapeutics, INC. | $20.50 | 2023 | Auvelity |
| Neurocrine Biosciences, INC. | $19.67 | 2022 | |
| Noven Therapeutics, LLC | $17.91 | 2025 | Secuado, Xelstrym |
| Indivior INC. | $17.62 | 2020 | |
| Neuronetics, INC. | $16.86 | 2020 | |
| Pfizer INC. | $15.19 | 2025 | |
| Alfasigma USA, INC. | $14.32 | 2020 | |
| Shire North American Group INC | $13.86 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pavan Pamadurthi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.